The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease
Open accessAbstract
BACKGROUND: The effectiveness of antiviral therapy in preventing disease progression in patients with chronic hepatitis B and advanced fibrosis or cirrhosis is unknown. METHODS: Patients with chronic hepatitis B who had histologically confirmed cirrhosis or advanced fibrosis were randomly assigned in a 2:1 ratio to receive lamivudine (100 mg per day) or placebo for a maximum of five years. Of 651 patients, 436 were assigned to receive lamivudine and 215 to receive placebo. The primary end point was time to disease progression, defined by hepatic decompensation, hepatocellular carcinoma, spontaneous bacterial peritonitis, bleeding gastroesophageal varices, or death related to liver disease. An independent data and safety monitoring board monitored the progress of the study and performed interim analyses of the data. RESULTS: We randomly assigned 651 patients (98 percent Asian and 85 percent male) to receive lamivudine or placebo. The study was terminated after a median duration of treatment of 32.4 months (range, 0 to 42) owing to a significant difference between treatment groups in the number of end points reached. End points were reached by 7.8 percent of the patients receiving lamivudine and 17.7 percent of those receiving placebo (hazard ratio for disease progression, 0.45; P=0.001). The Child-Pugh score increased in 3.4 percent of the patients receiving lamivudine and 8.8 percent of those receiving placebo (hazard ratio, 0.45; P=0.02), whereas hepatocellular carcinoma occurred in 3.9 percent of those in the lamivudine group and 7.4 percent of those in the placebo group (hazard ratio, 0.49; P=0.047). Genotypic resistance YMDD mutations developed in 49 percent of the patients treated with lamivudine, and the Child-Pugh score was more likely to increase in patients with these mutations than in the other patients treated with lamivudine (7 percent vs. <1 percent). Overall, 12 percent of the patients in the lamivudine group and 18 percent of the patients in the placebo group reported serious adverse events. CONCLUSIONS: Continuous treatment with lamivudine delays clinical progression in patients with chronic hepatitis B and advanced fibrosis or cirrhosis by significantly reducing the incidence of hepatic decompensation and the risk of hepatocellular carcinoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Lok, A. S. F., & McMahon, B. J. (2007) · Hepatology · doi:10.1002/hep.21513 · Cited by 3,087
HEPATOCELLULAR CARCINOMA AND HEPATITIS B VIRUS
Beasley, R. P., Lin, C.-C., Hwang, L.-Y., & Chien, C.-S. (1981) · The Lancet · doi:10.1016/s0140-6736(81)90585-7 · Cited by 2,865
A One-Year Trial of Lamivudine for Chronic Hepatitis B
Lai, C.-L., Chien, R.-N., Leung, N. W. Y., Chang, T.-T., Guan, R., Tai, D.-I., Ng, K.-Y., Wu, P.-C., Dent, J. C., Barber, J., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807093390201 · Cited by 1,754
Self-citationHepatitis B virus.The major etiology of hepatocellular carcinoma
Beasley, R. P. (1988) · Cancer · doi:10.1002/1097-0142(19880515)61:10<1942::aid-cncr2820611003>3.0.co;2-j · Cited by 1,280
Lamivudine as Initial Treatment for Chronic Hepatitis B in the United States
Dienstag, J. L., Schiff, E. R., Wright, T. L., Perrillo, R. P., Hann, H.-W. L., Goodman, Z., Crowther, L., Condreay, L. D., Woessner, M., Rubin, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910213411702 · Cited by 1,226
Hepatitis B e Antigen and the Risk of Hepatocellular Carcinoma
Yang, H.-I., Lu, S.-N., Liaw, Y.-F., You, S.-L., Sun, C.-A., Wang, L.-Y., Hsiao, C. K., Chen, P.-J., Chen, D.-S., & Chen, C.-J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013215 · Cited by 1,222
Self-citationLAMIVUDINE AS INITIAL TREATMENT FOR CHRONIC HEPATITIS B IN THE UNITED STATES
Ules, J., Ienstag, L. D., Chiff, E. U. R. S., Right, L. W., Errillo, R. O. P. P., Ann, L. H., Rowther, L. Y. C., Ondreay, D. C., Oessner, M. A. W., Ubin, M. A. R., et al. (1999) · Cited by 1,116
Long-Term Follow-up of HBeAg-Positive Patients Treated with Interferon Alfa for Chronic Hepatitis B
Niederau, C., Heintges, T., Lange, S., Goldmann, G., Niederau, C. M., Mohr, L., & Häussinger, D. (1996) · New England Journal of Medicine · doi:10.1056/nejm199605303342202 · Cited by 803
Cited by
Items 101–130 of 130
Choi, J., Kim, H. J., Lee, J., Cho, S., Ko, M. J., & Lim, Y.-S. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4070 · Cited by 282
RetractedShim, J. H., Lee, H. C., Kim, K. M., Lim, Y.-S., Chung, Y.-H., Lee, Y. S., & Suh, D. J. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2009.11.007 · Cited by 280
Hepatitis B virus PreS/S gene variants: Pathobiology and clinical implications
Pollicino, T., Cacciola, I., Saffioti, F., & Raimondo, G. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.04.041 · Cited by 277
Chen, G., Lin, W., Shen, F., Iloeje, U. H., London, W. T., & Evans, A. A. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00647.x · Cited by 275
Cabrera, R. (2012) · Hepatic Medicine: Evidence and Research · doi:10.2147/hmer.s16316 · Cited by 274
Chemopreventive strategies in hepatocellular carcinoma
Singh, S., Singh, P. P., Roberts, L. R., & Sanchez, W. (2014) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.143 · Cited by 273
Side effects of long-term oral antiviral therapy for hepatitis B
Fontana, R. J. (2009) · Hepatology · doi:10.1002/hep.22885 · Cited by 272
Kelloff, G. J., Lippman, S. M., Dannenberg, A. J., Sigman, C. C., Pearce, H. L., Reid, B. J., Szabo, E., Jordan, V. C., Spitz, M. R., Mills, G. B., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1104 · Cited by 270
Self-citationGuideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update)
Hou, J., Wang, G., Wang, F., Cheng, J., Ren, H., Zhuang, H., Sun, J., Li, L., Li, J., Meng, Q., et al. (2017) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2016.00019 · Cited by 270
Chen, C., Lee, W., Yang, H., Chang, H., Jen, C., Iloeje, U. H., Su, J., Hsiao, C. K., Wang, L., You, S., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.06.036 · Cited by 268
A heteroaryldihydropyrimidine activates and can misdirect hepatitis B virus capsid assembly
Stray, S. J., Bourne, C. R., Punna, S., Lewis, W. G., Finn, M. G., & Zlotnick, A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409732102 · Cited by 267
Hui, C., Leung, N., Yuen, S., Zhang, H., Leung, K., Lu, L., Cheung, S. K. F., Wong, W., & Lau, G. K. (2007) · Hepatology · doi:10.1002/hep.21724 · Cited by 266
Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs
Locarnini, S., Hatzakis, A., Chen, D.-S., & Lok, A. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.01.018 · Cited by 262
Woo, G., Tomlinson, G., Nishikawa, Y., Kowgier, M., Sherman, M., Wong, D. K. H., Pham, B., Ungar, W. J., Einarson, T. R., Heathcote, E. J., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.06.042 · Cited by 259
Kim, G.-A., Lim, Y.-S., Han, S., Choi, J., Shim, J. H., Kim, K. M., Lee, H. C., & Lee, Y. S. (2018) · Gut · doi:10.1136/gutjnl-2017-314904 · Cited by 258
Yuen, M.-F., Seto, W.-K., Chow, D. H.-F., Tsui, K., Wong, D. K.-H., Ngai, V. W.-S., Wong, B. C.-Y., Fung, J., Yuen, J. C.-H., & Lai, C.-L. (2007) · Antiviral Therapy · doi:10.1177/135965350701200816 · Cited by 257
Keeffe, E. B., Zeuzem, S., Koff, R. S., Dieterich, D. T., Esteban–Mur, R., Gane, E. J., Jacobson, I. M., Lim, S. G., Naoumov, N., Marcellin, P., et al. (2007) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2007.05.004 · Cited by 257
Lange, C. M., Bojunga, J., Hofmann, W. P., Wunder, K., Mihm, U., Zeuzem, S., & Sarrazin, C. (2009) · Hepatology · doi:10.1002/hep.23346 · Cited by 255
Evolution of multi-drug resistant hepatitis B virus during sequential therapy
Yim, H. J., Hussain, M., Liu, Y., Wong, S. N., Fung, S. K., & Lok, A. S. F. (2006) · Hepatology · doi:10.1002/hep.21290 · Cited by 253
Liu, S. B., Ikenaga, N., Peng, Z., Sverdlov, D. Y., Greenstein, A., Smith, V., Schuppan, D., & Popov, Y. (2016) · The FASEB Journal · doi:10.1096/fj.14-268425 · Cited by 224
Choi, H. S. J., Brouwer, W. P., Zanjir, W. M. R., de Man, R. A., Feld, J. J., Hansen, B. E., Janssen, H. L. A., & Patel, K. (2020) · Hepatology · doi:10.1002/hep.30857 · Cited by 211
Lin, C.-W., Lin, C.-C., Mo, L.-R., Chang, C.-Y., Perng, D.-S., Hsu, C.-C., Lo, G.-H., Chen, Y.-S., Yen, Y.-C., Hu, J.-T., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2012.11.045 · Cited by 174
Epidemiology and prevention of hepatitis B virus infection
Kwon, S. Y., & Lee, C. H. (2011) · The Korean Journal of Hepatology · doi:10.3350/kjhep.2011.17.2.87 · Cited by 171
Self-citationTateishi, R., Okanoue, T., Fujiwara, N., Okita, K., Kiyosawa, K., Omata, M., Kumada, H., Hayashi, N., & Koike, K. (2015) · Journal of Gastroenterology · doi:10.1007/s00535-014-0973-8 · Cited by 170
Fung, S., Kwan, P., Fabri, M., Horban, A., Pelemis, M., Hann, H.-W., Gurel, S., Caruntu, F. A., Flaherty, J. F., Massetto, B., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.12.028 · Cited by 147
Abramovitch, S., Sharvit, E., Weisman, Y., Bentov, A., Brazowski, E., Cohen, G., Volovelsky, O., & Reif, S. (2015) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00132.2013 · Cited by 82
The cost-effectiveness of screening for chronic hepatitis B infection in the United States
Eckman, M. H., Kaiser, T. E., & Sherman, K. E. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir199 · Cited by 80
Review article: the reversibility of cirrhosis
Sohrabpour, A. A., Mohamadnejad, M., & Malekzadeh, R. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12044 · Cited by 80
LOXL2—A New Target in Antifibrogenic Therapy?
Puente, A., Fortea, J. I., Cabezas, J., Arias Loste, M. T., Iruzubieta, P., Llerena, S., Huelin, P., Fábrega, E., & Crespo, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071634 · Cited by 79
“In a multicenter randomized placebo-controlled trial involving 651 patients with HBV cirrhosis [27], lamivudine decreased the risk of severe liver complications (7.”
BackgroundMortality from cirrhosis: lack of progress over the last 35 years
Gluud, C. (2005) · Gut · doi:10.1136/gut.2005.072876 · Cited by 17
Metadata
- Authors
- Liaw, Y.-F., Sung, J. J. Y., Chow, W. C., Farrell, G., Lee, C.-Z., Yuen, H., Tanwandee, T., Tao, Q.-M., Shue, K., Keene, O. N., Dixon, J. S., Gray, D. F., & Sabbat, J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-10-07
- Volume
- 351
- Issue
- 15
- Pages
- 1521-1531
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2004054613
- Cited by
- 2,266
- References
- 31
- FWCI
- 76.31
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.